Life science companies Tecan and Dynal (a subsidiary of Invitrogen Corporation) have joined forces, combining Tecan's powerful Freedom EVO® automated liquid handling platforms with Dynal Biotech's Dynabeads® magnetic bead technology for isolation of any biological starting material, including mRNA, DNA and recombinant proteins. The flexibility of the Freedom EVO series of platforms offering a variety of liquid handling and robotic arm options complements the Dynabeads, whose compatibility with a wide variety of molecular tags makes it possible to isolate and concentrate cells, DNA, mRNA, organelles and proteins from the most difficult sources.

Tecan and Dynal Biotech have jointly developed several application-specific protocols, including the recombinant protein purification procedure, which combines Tecan's Te-MagS™ magnetic separation technology with Dynabeads' TALON™ system to isolate histidine affinity-tagged proteins from lysed cells. The Dynabeads mRNA Direct™ Kit rapidly isolates pure, intact mRNA from lysates of biological tissues using a Freedom EVO platform with a Tecan Te-MO™ 96-channel pipetting module and robotic manipulator arm. Dynabeads are also effective with this equipment in the Sequencing Clean-Up system, for consistent, high quality purification of DNA sequencing reactions.

Whatever the application, multiple batches of Dynabead-isolated samples can be processed with Tecan's Freedom EVO platforms without any user intervention, making higher throughput easy to achieve.

About Tecan

Tecan (www.tecan.com) is a leading player in the Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Through its subsidiary REMP (www.remp.com) Tecan is a leading supplier of compound and sample storage, managerial and logistic solutions. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2004, Tecan achieved sales of CH 286.0 million (USD 230.6 million; EUR 185.7 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor: 1210019).

For further information please contact:

Tecan Switzerland AG
Seestrasse 103
CH-8708 Männedorf

T +41 44 922 81 11
F +41 44 922 81 12
www.tecan.com